Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study on the Effects and Mechanisms of Probiotic Supplementation in Ameliorating Uric Acid Metabolism in Asymptomatic Hyperuricemic Individuals

11. juni 2026 opdateret af: Huicui Meng, Sun Yat-sen University
This study aims to utilize a randomized controlled trial in asymptomatic hyperuricemic individuals to clarify the effects of four probiotic strains including Lactobacillus acidophilus on serum uric acid levels, pathways of uric acid synthesis, degradation and excretion, hyperuricemia-induced oxidative stress and chronic inflammatory responses, uric acid-related metabolites, gut microbiota composition and diversity.

Studieoversigt

Status

Ikke rekrutterer endnu

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

68

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Guangdong
      • Shenzhen, Guangdong, Kina, 518107

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Men and women aged 18-65;
  • Residents who have lived in Guangdong for more than one year;
  • According to the "Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia-Related Diseases (2023 Edition)", asymptomatic HUA is defined as a fasting serum uric acid level >420 umol /L and no history of gout symptoms such as gouty arthritis;
  • Consent to be randomly assigned to the intervention or control group;
  • Willing to consume the probiotic products provided by the study;

Exclusion Criteria:

  • Secondary HUA caused by disease or drugs;
  • Within 3 months before participating in the study, or currently taking drugs that affect uric acid metabolism, such as azathioprine, thiazide diuretics, prednisone, etc., and unwilling to stop taking them during the study;
  • Taking or currently taking medication for gout within 3 months before participating in the study and unwilling to stop taking it during the study;
  • Abnormal liver function (AST or ALT levels are more than 3 times the upper limit of normal), abnormal renal function (glomerular filtration rate less than 60mL/min/1.73m^2);
  • Abnormal blood test results (such as white blood cell count < 3.5x10^9 /L, platelet count < 100x10^9 /L, hemoglobin < 90g/L) or other blood system diseases;
  • Suffering from severe cardiovascular, kidney, gastrointestinal, hepatal, and malignant tumor diseases;
  • Long-term or current use of nonsteroidal anti-inflammatory drugs, antibiotics, antihistamines, or immunomodulatory drugs, and inability to stop using these drugs within 72 hours before the start of the study;
  • Currently taking anticoagulants, anabolic steroids, hydrocortisone and other hormonal drugs;
  • Use of probiotic supplements within one month prior to participating in the study, and was unwilling to discontinue taking them during the study;
  • Frequent use (more than once a day) of multivitamins, antioxidants, herbal supplements, dietary fiber-containing supplements, and other nutritional supplements (such as inulin, fish oil, soy lecithin, niacin, dietary fiber, flaxseed, phytoestrogens, sterols, etc.), or products containing prebiotics, probiotics, synbiotics, postbiotics, etc. (such as yogurt, fermented milk, beverages, or other fermented products) within 3 months prior to study participation, and unwilling to stop taking them;
  • Self-reported weight loss of more than 7 kg or 10% in the 6 months prior to enrollment;
  • Suffering from eating disorders (such as anorexia and bulimia), dysphagia, or difficulty swallowing food or medication;
  • Unable to consume the probiotic products provided by the study as required during the study period;
  • Drink more than 2 times a day, more than 14 times a week, and are unwilling to stop drinking during the study;
  • Intolerance or food allergy related to the investigational product, drug allergy, or other issues that may affect food intake;
  • Poor venous access;
  • Women who have given birth in the past year, are pregnant, or plan to become pregnant within 6 months, or are breastfeeding;
  • Participating or planning to participate in other dietary intervention studies, drug use studies, or cosmetic or pharmaceutical application studies in the next three months;
  • Participated in clinical trials in the past 3 months;
  • Any other condition that is deemed unsuitable for the trial by a physician.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo kontrol
Placebo (without probiotics, with other ingredients consistent with probiotic products)
Eksperimentel: Probiotic intervention
Probiotic products (6 × 10^9 CFU per day)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Blood uric acid
Tidsramme: Weeks 0,4,8
Weeks 0,4,8

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood urea nitrogen
Tidsramme: Weeks 0,4,8
Weeks 0,4,8
Blood creatinine
Tidsramme: Weeks 0,4,8
Weeks 0,4,8
Blood xanthine
Tidsramme: Weeks 0,8
Weeks 0,8
Blood hypoxanthine
Tidsramme: Weeks 0,8
Weeks 0,8
Blood xanthine oxidase
Tidsramme: Weeks 0,8
Weeks 0,8
Fecal uric acid
Tidsramme: Weeks 0,8
Weeks 0,8
Fecal allantoin
Tidsramme: Weeks 0,8
Weeks 0,8
Urine uric acid
Tidsramme: Weeks 0,8
Weeks 0,8
Urine allantoin
Tidsramme: Weeks 0,8
Weeks 0,8
Serum diamine oxidase
Tidsramme: Weeks 0,8
Weeks 0,8
Urine oxidative stress indicator level
Tidsramme: Weeks 0,8
Weeks 0,8
Blood inflammatory cytokine levels
Tidsramme: Weeks 0,8
Quantitative measurement of chronic inflammatory biomarkers in blood serum or plasma, such as high-sensitivity C-reactive protein (hs-CRP).
Weeks 0,8
Fecal gut microbiota
Tidsramme: Weeks 0,8
Analyzing the composition of gut microbiota using metagenomic sequencing technology. DNA will be extracted from fecal samples using commercial kits, followed by library preparation and sequencing.
Weeks 0,8
Metabolomics
Tidsramme: Weeks 0,8
Non-targeted metabolomics using LC-MS (liquid chromatography-mass spectrometry).
Weeks 0,8

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juli 2026

Primær færdiggørelse (Anslået)

31. oktober 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

1. juni 2026

Først indsendt, der opfyldte QC-kriterier

11. juni 2026

Først opslået (Faktiske)

16. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. juni 2026

Sidst verificeret

1. marts 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SYSU PH (SZ) ME [2026] 041

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner